Last update 23 Jan 2025

Minghui Pharmaceutical Pty Ltd

Private Company

Overview

Tags

Neoplasms
Respiratory Diseases
Antibody drug conjugate (ADC)

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Neoplasms2
Top 5 Drug TypeCount
Antibody drug conjugate (ADC)2
Top 5 TargetCount
TOP(Topoisomerases)1
CD276(CD276 antigen)1

Related

3
Drugs associated with Minghui Pharmaceutical Pty Ltd
Tofacitinib etocomil
Target
JAK
Mechanism
JAK inhibitors
Active Org.
Minghui Pharmaceutical (Hangzhou) Co., Ltd.Startup
Originator Org.
Minghui Pharmaceutical (Shanghai) Co., Ltd.
Active Indication
Mild Atopic Dermatitis [+2]
Inactive Indication
Autoimmune Diseases [+1]
Drug Highest PhasePhase 3
First Approval Ctry. / Loc.-
First Approval Date-
MHB088C
Target
CD276
Mechanism
CD276 inhibitors
Active Org.
Minghui Pharmaceutical Pty Ltd [+1]
Originator Org.
Minghui Pharmaceutical Pty Ltd
Active Indication
Advanced Malignant Solid Neoplasm
Inactive Indication-
Drug Highest PhasePhase 1/2
First Approval Ctry. / Loc.-
First Approval Date-
MHB036C
Target
TOP
Mechanism
TOP inhibitors
Active Org.
Minghui Pharmaceutical (Hangzhou) Co., Ltd.Startup [+1]
Originator Org.
Minghui Pharmaceutical Pty Ltd
Active Indication
Advanced Malignant Solid Neoplasm [+1]
Inactive Indication-
Drug Highest PhasePhase 1/2
First Approval Ctry. / Loc.-
First Approval Date-
3
Clinical Trials associated with Minghui Pharmaceutical Pty Ltd
NCT05642949
/ Not yet recruitingPhase 1/2
Phase 1/2, Multi-center, Open-label, Dose Escalation and Cohort Expansion Study to Evaluate the Safety/Tolerability, Pharmacokinetics and Efficacy of MHB036C in Participants With Advanced or Metastatic Solid Tumors
NCT05652855
/ Not yet recruitingPhase 1/2
Phase 1/2, Two-Part, Multi-center, Open-label, Dose Escalation and Dose Expansion First-In-Human Study to Evaluate the Safety/Tolerability, Pharmacokinetics and Efficacy of MHB088C in Participants With Advanced or Metastatic Solid Tumors
NCT04815148
/ Unknown statusPhase 1
A Phase Ia/Ib Study to Evaluate the Safety, Tolerability and PK of MH004 Topical Cream in Healthy Adult Volunteers and to Investigate Its Efficacy and Safety Profile in Participants With Atopic Dermatitis or Rheumatoid Arthritis
100 Clinical Results associated with Minghui Pharmaceutical Pty Ltd
Login to view more data
0 Patents (Medical) associated with Minghui Pharmaceutical Pty Ltd
Login to view more data
100 Deals associated with Minghui Pharmaceutical Pty Ltd
Login to view more data
100 Translational Medicine associated with Minghui Pharmaceutical Pty Ltd
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 22 Feb 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Phase 2 Clinical
2
1
Other
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
MHB036C
 ( TOP )		Advanced Malignant Solid Neoplasm
More
Phase 2 Clinical
MHB088C
 ( CD276 )		Advanced Malignant Solid Neoplasm
More
Phase 2 Clinical
Tofacitinib etocomil
 ( JAK )		Rheumatoid Arthritis
More
Pending
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free